SOPHiA GENETICS (SOPH) Stock Price
SOPHiA GENETICS Price
Over the last 6 years SOPHiA GENETICS grew revenue by 20.0% annually, reaching 72.72 M USD. For SOPHiA GENETICS, the net margin of -108.6% is up versus -185.2% a few years ago. The consensus 12-month price target for SOPHiA GENETICS is 11.50 USD, about 57.3% above where the stock trades today. Of 11 analysts, 10 rate the stock a buy — an overall Buy consensus.
SOPHiA GENETICS stock price
SOPHiA GENETICS business model & stock analysis
Frequently asked questions about SOPHiA GENETICS
The business model of Sophia Genetics SA is focused on providing advanced data analytics solutions for genomic testing. Sophia Genetics offers a cloud-based platform that utilizes artificial intelligence (AI) and machine learning algorithms to analyze genetic data and assist healthcare professionals in making more accurate diagnoses and treatment decisions. They collaborate with a wide network of medical laboratories worldwide, helping to improve the accessibility and efficiency of genomic testing. With their comprehensive suite of solutions, Sophia Genetics aims to drive precision medicine and enable personalized healthcare on a global scale.
Sophia Genetics SA is primarily active in the healthcare and biotechnology industries.
The main competitors of Sophia Genetics SA in the market include companies such as Illumina, Thermo Fisher Scientific, and Qiagen.
Sophia Genetics SA is a leading healthtech company specializing in data-driven medicine and advanced genomic analysis. Founded in 2011 by Jurgi Camblong and Pierre Hutter, the company has since revolutionized the field of clinical genomics. Sophia Genetics uses artificial intelligence and machine learning to analyze patients' genomic data, providing accurate diagnoses and personalized treatment recommendations. With offices in Switzerland, the United States, and other countries, Sophia Genetics has collaborated with over 1,000 hospitals worldwide, improving patient care and outcomes. This company has quickly gained global recognition for its innovative solutions, which harness the power of genomics to transform healthcare.
Some significant milestones achieved by Sophia Genetics SA include securing a strategic partnership with Illumina, a global leader in DNA sequencing and array-based technologies. The company also expanded its genomic analysis platform to cover a wide range of genetic diseases, enabling more efficient and accurate diagnoses. Sophia Genetics SA has gained recognition by joining forces with renowned academic institutions and leading hospitals worldwide. Additionally, the company has received various prestigious awards, including being named a Global Cleantech prestigious 100 company. These achievements showcase Sophia Genetics SA's commitment to advancing genomic medicine and revolutionizing healthcare through innovative solutions and collaborations.
Sophia Genetics SA is primarily present in various countries and regions across the globe. Some of the key areas where the company has a significant presence include Europe, North America, Asia-Pacific, and the Middle East. With their advanced genomic data analysis solutions and services, Sophia Genetics SA has gained recognition and partnerships with renowned institutions, hospitals, and research centers in numerous countries. Their presence spans across multiple continents, making them a global leader in the field of genomics and personalized medicine.
Sophia Genetics SA represents values of innovation, collaboration, and integrity in the field of genetic testing and analysis. The company believes in harnessing the power of data and technology to revolutionize healthcare delivery. Sophia Genetics SA's corporate philosophy is centered around democratizing genomics, making it accessible and affordable for all. By providing advanced solutions for genomic data analysis, the company aims to empower healthcare professionals in making informed decisions and improving patient outcomes. Sophia Genetics SA's commitment to accuracy, transparency, and continuous research drives its mission to transform the future of personalized medicine.
Analysts currently set an average price target of 11.50 USD for the SOPHiA GENETICS stock (median: 11.50 USD), implying +57.3 % versus the latest price. The consensus is based on 11 analyst ratings.
11 analysts currently rate the SOPHiA GENETICS stock: 10 recommend buying, 1 holding and 0 selling. For 2026, analysts expect SOPHiA GENETICS to generate revenue of 95.26 M USD and earnings per share of -0.93 USD.
Converted at the current exchange rate, the SOPHiA GENETICS share trades at 6.53 EUR (7.31 USD).
The SOPHiA GENETICS share (SOPH) is listed on 2 stock exchanges, including: NASDAQ (SOPH), Frankfurt (90B.F).
Sophia Genetics SA is a Swiss company that specializes in providing advanced solutions for the analysis of genomic data. They work closely with leading hospitals and research institutions as part of their mission to improve healthcare. The business model of Sophia Genetics includes providing bioinformatics solutions to hospitals and clinics, using artificial intelligence and machine learning to improve clinical genomics and help doctors and researchers identify genetic anomalies and mutations faster and more accurately. Another important area of Sophia Genetics' business is collaboration with pharmaceutical companies in the development of personalized medicines. They collect and analyze data from patients with specific diseases to develop and test personalized treatment options. These partnerships also provide Sophia Genetics with access to large-scale studies and databases that provide more information about certain diseases. Sophia Genetics also offers a range of specialized products, including SOPHiA DDM, SOPHiA GENETICS Clinical Insights, SOPHiA AI Platform, and SOPHiA Solid Tumor Solution. SOPHiA DDM is a cloud-based platform that allows medical professionals and researchers to analyze genomic data and draw conclusions about diseases and treatment options. SOPHiA GENETICS Clinical Insights provides real-time interpretation support for the diagnosis and treatment of patients. SOPHiA AI Platform is an AI-based solution that helps interpret genomic data. SOPHiA Solid Tumor Solution is a diagnostic tool specialized in identifying genetic anomalies in tumor tissue samples. Sophia Genetics' technology is also applicable to a variety of industries, such as the agricultural industry. They collaborate with global biotechnology companies to develop new plant varieties and optimize agricultural processes. Over the years, Sophia Genetics has built numerous partnerships and collaborations with leading institutions and companies in the healthcare and bioinformatics industry. Their customers include hospitals, diagnostic laboratories, biorepositories, and pharmaceutical companies in Europe, North America, the Middle East, Africa, and Asia. In summary, the business model of Sophia Genetics SA is based on providing innovative bioinformatics solutions. They collaborate with leading institutions in the healthcare and bioinformatics industry and offer specialized products to improve the diagnosis and treatment of patients and develop personalized medicines. Their focus on collaboration with pharmaceutical companies and medical institutions, as well as the applicability of their technology to other industries, has made Sophia Genetics a key player in the journey towards personalized medicine.
The expected revenue of SOPHiA GENETICS is 95.26 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of SOPHiA GENETICS is -63.64 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of SOPHiA GENETICS is currently -7.84. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the SOPHiA GENETICS stock.
The price-to-sales ratio (P/S) of SOPHiA GENETICS is currently 5.24. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the SOPHiA GENETICS stock.
The Eulerpool Quality Score for SOPHiA GENETICS is 3/10.
The ISIN of SOPHiA GENETICS is CH1125843347. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of SOPHiA GENETICS is A3CVT8. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of SOPHiA GENETICS is SOPH. The ticker symbol is used to trade SOPHiA GENETICS shares on the stock exchange.
SOPHiA GENETICS stock
SOPHiA GENETICS Peer Group
SOPHiA GENETICS Ticker
SOPHiA GENETICS FIGI
All fundamentals and in-depth analysis of SOPHiA GENETICS
Our stock analysis for SOPHiA GENETICS stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of SOPHiA GENETICS. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.